MET and non-small cell lung carcinoma: Yet new data show that Crizotinib-treated NSCLC patients with wildtype (wt) EGFR and high-level MET amplification may achieve a median OS of >11 months and that Crizotinib is more effective than chemotherapy or immunotherapy as first-line therapy in this setting [16,17].